Loading…
← CockpitCompetitor Analysis › ATEC Alphatec Holdings, Inc.Open in the cockpit ↗

Alphatec Holdings, Inc.ATECCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of spine surgery implants and technology, including screws, cages and navigation/robotics systems.

Momentum laggard 19
Mkt cap
$1.10B
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$48.6M
20-day average traded
Fwd P/E
15.1×
forward earnings
ROIC−WACC
-11.7 pp
WACC 8.1%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$7.06
1D+1.7%
1W-4.0%
1M-35.0%
3M-24.0%
6M-14.3%
YTD-66.4%
1Y-64.5%
ATR %8.4%
Beta1.35
52w lowhigh69.7% off high

What Alphatec does

Maker of spine surgery implants and technology, including screws, cages and navigation/robotics systems.

Earns per spine surgery, selling the implants and the instrument sets and technology around them, and grows by signing surgeons who adopt its full set of tools. It bought the French imaging company EOS imaging in 2021 to supply pre-surgery planning that complements the implants.

Products and services

  • Spinal implants (screws, cages, plates)
  • Surgical navigation/robotics (EOS/Valence)
  • Minimally invasive spine surgery instruments

Customers

  • Spine surgeons
  • Hospitals/ambulatory surgery centers

Where it sits in the supply chain

  • Medical devices
  • Spine surgery devices
  • Spinal implants, instrumentation…

What could go right

  • Spine surgery volume growth
  • Market-share gains from navigation ecosystem

What could go wrong

  • High leverage/interest expense
  • Competitive spine-implant pricing pressure

Moat: narrow (switching costs, process know-how). Integrated implant-plus-navigation ecosystem builds surgeon workflow lock-in versus standalone implant makers.

Headquarters: Carlsbad, California · Founded: 1990 · Employees: 913

Named competitors

Alphatec at a glance

Size Alphatec (ATEC) is a United States Health Care company (Medical Specialties) with a market value of $1.10B, the 2169th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.06 on 18 Nov 2026.

Performance Over six months the shares fell 14.3%, against -4.5% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue grew 15.3% over the last twelve months (peer median +8.3%); the operating margin is -3.0% (peer median 11.6%).

Valuation It trades at 15.1× forward earnings against a peer median of 18.5× (4th cheapest of 12).

Capital Return on invested capital runs 11.7 points below its cost of capital (8.1% WACC).

Credit Alphatec has 1 bond outstanding ($405M).

Short interest Short interest is 9.2% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 95ATEC 86
Six months, rebased to 100: Alphatec against the median of its 20 peers (local-currency closes).

Alphatec financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$840M$764M$612M$482M$351M
Revenue growth—+25%+27%+37%—
Gross profit$520M$454M$346M$254M$192M
EBITDA$58.2M$24.6M-$39.6M-$88.6M-$77.2M
Net income-$86.9M-$143M-$162M-$187M-$151M
Free cash flow$3.07M$2.78M-$128M-$159M-$125M
Capital expenditure$71.8M$49.6M$93.1M$87.0M$58.3M
Total debt$594M$596M$610M$542M$396M

Quarterly statements and history in the cockpit →

Alphatec competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%DRTS214150IART301101688622SIBN300406IRMD688161CSTLEUZ6000553010216523300685TNDM300206CBLL2675ATEC6-month return →1-month return →
Up and to the right = strong over both horizons. Alphatec is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×214150IART301101300406IRMD68816165232675ATECRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alphatec is the large dot.

Alphatec competitors and peer comparison

Head to head with its named competitors (ATEC vs MDT vs GMED vs SYK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Alphatec ATEC$1.10B-14%+15%-3%15.1×n/a
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Globus Medical GMED$9.34B-16%+13%23%13.7×4.6%
Stryker SYK$121B-1%+8%25%19.9×10.7%

How Alphatec compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alphatec against its 20 peers (data as of 18 Nov 2026)
MeasureATECPeer medianRank in peer set
1-month return-35.0%-5.1%lowest of 21
6-month return-14.3%-4.5%8th lowest of 20
Distance from 52-week high-69.7%-29.4%2nd lowest of 21
Revenue growth (TTM)+15.3%+8.3%5th highest of 19
Operating margin-3.0%11.6%6th lowest of 20
Forward P/E15.1×18.5×4th cheapest of 12
ROIC minus cost of capital-11.7 pp+0.3 pp6th lowest of 19
EV / EBITDA28.0×8.5×2nd most expensive of 7
Net debt / EBITDA8.8×-0.8×most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%n/an/an/a
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%2%120.2×n/an/a

Alphatec bonds and credit

Alphatec has 1 bond outstanding with $405M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Alphatec's main competitors?
Named competitors: Medtronic (MDT), Globus Medical (GMED), Stryker (SYK). The cockpit's measured peer set (industry) also includes Freenome (FRNM), Alpha Tau Medical (DRTS), CLASSYS (214150.KS), Integra LifeSciences (IART), Mingyue Optical Lens (301101.SZ), Guangzhou Hexin Instrument (688622.SS).
Is Alphatec expensive compared with its peers?
On forward p/e it trades at 15.1× against a peer median of 18.5×, 4th cheapest of 12 in its peer set.
How has Alphatec stock performed?
Over six months to 18 Nov 2026 the shares returned -14.3% against -4.5% for the median peer; over one year -64.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.